In the Kiupel high-grade MCT subset treated with adjunctive therapy, what is the hazard ratio for survival for dogs with high Beclin-1 expression versus low Beclin-1 expression in primary tumors?

• A. 2.5
• B. 1.0
• C. 16.3
• D. 18.9

Answer: (C)

Hazard ratio interpretation in survival analysis shows how much more (or less) likely an event is to happen at any moment in one group compared with another. In this Kiupel high-grade canine MCT study, within dogs treated with adjunctive therapy, high Beclin-1 expression in primary tumors is associated with a hazard ratio of 16.3 versus low Beclin-1 expression. This means that at any point after treatment, dogs with high Beclin-1 have about 16 times the risk of death (or the study’s endpoint) compared with dogs with low Beclin-1.

Beclin-1 is a key regulator of autophagy, a process that can help tumor cells survive under stress, including chemotherapy or other adjunctive therapies. A much higher hazard ratio suggests that tumors with elevated Beclin-1 expression are more capable of using autophagy to endure treatment, leading to substantially shorter survival in this subgroup.

This substantial effect highlights Beclin-1 expression in primary tumors as a strong prognostic indicator in this context. Of course, interpretation should consider confidence intervals and study design, but the value points to a notably worse prognosis when Beclin-1 is high.